| Project 1: Interrogating Cyclin-Dependent-Kinase Inhibitors As A Novel Treatment Strategy For Glioblastoma Patients |
|
Location: Royal College of Surgeons in Ireland Principal Investigator: Dr Brona Murphy Collaborators: Prof Markus Morrison (University of Stuttgart, Germany), Dr Verena Murphy (Cancer Trials Ireland) |
| Project 2: Development of a validated mathematical model to predict GBM responsiveness to the translationally relevant TRAIL-variant IZI1551 |
|
Location: University of Stuttgart, Germany Principle Investigator: Prof Markus Morrison Collaborators: Dr Brona Murphy (Royal College of Surgeons in Ireland), Dr Lothar Terfloth (In silico Biotechnology, Germany) |
| Project 3: Development and testing of a CNS-penetrating variant of the translationally relevant TRAIL-variant IZI1551 |
|
Location: University of Stuttgart, Germany Principle Investigator: Prof Markus Morrison Collaborators: Dr Thomas Schirrmann (YUMAB, Germany), Prof Annette Byrne (Royal College of Surgeons in Ireland) |
| Project 4: Pre-clinical interrogation of checkpoint inhibitor immunotherapy in GBM implementing ultrasound (US)-induced opening of the BBB |
|
Location: ICM Institute for Brain and Spinal Cord, France Principle Investigator: Dr Ahmed Idbaih Collaborators: Prof Markus Morrison (University of Stuttgart, Germany), Racim Bouabdallah, MD (Bristol Myers Squibb, France), Frederic Sottilini (CarThera, France), Dr Maria Mancini (Champions Oncology, United States of America) |
| Project 5: Identifying new Tumour Microenvironment (TME) contexts of vulnerability in Glioblastoma |
|
Location: Royal College of Surgeons in Ireland (RCSI Dublin City Centre Campus) Principle Investigator: Prof Annette Byrne Collaborators: Prof Diether Lambrechts (Vlaams Instituut voor Biotechnologie (VIB) Leuven, Belgium), Dr Maria Mancini (Champions Oncology, Baltimore, USA) |
| Project 6: Investigating intratumoural GBM heterogeneity in the context of antiangiogenic immune therapies |
|
Location: Vlaams Instituut voor Biotechnologie, Belgium Principle Investigator: Prof Gabriele Bergers Collaborators: Oncurious, Belgium |
| Project 7: Drug repurposing of available anti-cancer agents for precision therapy of GBM patients |
|
Location: Erasmus University Rotterdam, The Netherlands Principle Investigator: Dr Martine Lamfers Collaborators: Prof Jochen Prehn (Royal College of Surgeons in Ireland), Mr Hennie Henrichs (Teva Pharmaceutical Industries, The Netherlands) |
| Project 8: Genomic biomarker driven approach to better identify GBM patient responders to SOC therapy |
|
Location: Vlaams Instituut voor Biotechnologie, Belgium Principle Investigator: Prof Diether Lambrechts |